+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myocardial Ischemia - Pipeline Review, H1 2020

  • ID: 4997727
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 88 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Angionetics Inc
  • Bayer AG
  • Caladrius Biosciences Inc
  • CohBar Inc
  • NoNO Inc
  • Q BioMed Inc
  • MORE
Myocardial Ischemia - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2020, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Angionetics Inc
  • Bayer AG
  • Caladrius Biosciences Inc
  • CohBar Inc
  • NoNO Inc
  • Q BioMed Inc
  • MORE
Introduction
Report Coverage
Myocardial Ischemia - Overview
Myocardial Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Ischemia - Companies Involved in Therapeutics Development
Angionetics Inc
AstraZeneca Plc
Bayer AG
Cadrock Pty Ltd
Caladrius Biosciences Inc
Cellmid Ltd
Chrysalis BioTherapeutics Inc
CohBar Inc
Everon Biosciences Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Lixte Biotechnology Holdings Inc
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc
Myocardial Ischemia - Drug Profiles
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azithromycin + doxycycline + rifabutin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMX-4.80P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Myocardial Ischemia - Product Development Milestones
Featured News & Press Releases
Feb 20, 2019: Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A as a regenerative therapeutic
Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2020
Myocardial Ischemia - Pipeline by AstraZeneca Plc, H1 2020
Myocardial Ischemia - Pipeline by Bayer AG, H1 2020
Myocardial Ischemia - Pipeline by Cadrock Pty Ltd, H1 2020
Myocardial Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2020
Myocardial Ischemia - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Myocardial Ischemia - Pipeline by CohBar Inc, H1 2020
Myocardial Ischemia - Pipeline by Everon Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
Myocardial Ischemia - Pipeline by NoNO Inc, H1 2020
Myocardial Ischemia - Pipeline by Omniox Inc, H1 2020
Myocardial Ischemia - Pipeline by Q BioMed Inc, H1 2020
Myocardial Ischemia - Pipeline by Symvivo Inc, H1 2020
Myocardial Ischemia - Pipeline by Vasade Biosciences Inc, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Myocardial Ischemia - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Angionetics Inc
  • AstraZeneca Plc
  • Bayer AG
  • Cadrock Pty Ltd
  • Caladrius Biosciences Inc
  • Cellmid Ltd
  • Chrysalis BioTherapeutics Inc
  • CohBar Inc
  • Everon Biosciences Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Lixte Biotechnology Holdings Inc
  • NoNO Inc
  • Omniox Inc
  • Q BioMed Inc
  • Symvivo Inc
  • Vasade Biosciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll